<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39420134</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Systematic review and meta analysis of cross immunity and the smokers paradox in COVID19.</ArticleTitle><Pagination><StartPage>24344</StartPage><MedlinePgn>24344</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24344</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75632-6</ELocationID><Abstract><AbstractText>COVID-19 pandemic, caused by the novel SARS-CoV-2 virus, has raised significant interest in understanding potential cross-immunity mechanisms. Recent evidence suggests that T-cells associated with common cold coronaviruses (229E, NL63, OC43, HKU1) may provide some level of cross-immunity against SARS-CoV-2. It is also known that the prevalence of smokers among patients admitted to hospital for COVID-19 is lower than expected according to the corresponding country's smoking prevalence, which is known as smoker's paradox in COVID-19. No clear consensus to explain it has yet been reached. This phenomenon suggests a complex interaction between smoking and immune response. Nonetheless, very few works have studied the prevalence of smokers in those infected by common cold coronaviruses, and its relation to COVID-19 has not been investigated. We performed a systematic review and meta-analysis to study the prevalence of smokers among patients infected by common cold coronaviruses, and to compare them to the corresponding country's smoking prevalence. L'Abbé plots were used to visually assess the consistency of the observed effects across the different studies included in the meta-analysis. Additionally, significant differences were found in smoking prevalence among the various types of ccCoV, indicating the need for further research into the biological mechanisms driving these disparities. The results show that smoking prevalence is higher among those patients infected by these coronaviruses than in the general population (OR = 1.37, 95% CI: 0.81-2.33). A study was separately done for the four coronavirus types, and the prevalence of smokers was higher in three of the four than that corresponding to country, gender and study year: OC43 (OR = 1.93, 95% CI: 0.64-5.82); HKU1 (OR = 3.62, 95% CI: 1.21-10.85); NL63 (OR = 1.93, 95% CI: 0.64-5.82); 229E (OR = 0.97, 95% CI: 0.50-1.90). The heterogeneity of the studies was assessed using the Cochrane Chi-squared test, I-squared (I2), and Tau-squared (τ2). This detailed statistical analysis enhances the robustness of our findings and highlights the variations in smoking prevalence among different ccCoVs. Our data suggest that COVID-19 might be less prevalent among smokers due to greater cross-immunity from a larger number or more recent infections by common cold coronaviruses than the non-smoking population, which would explain smoker's paradox in COVID-19. IMPLICATIONS. The low prevalence of current smokers among SARS-CoV-2 patients is a finding recurrently repeated, even leading to postulate the "smoker's paradox" in COVID-19. This fact compelled us to study the prevalence of smokers among patients infected by common cold coronaviruses, and to compare them to the corresponding country's smoking prevalence. Our data could explain smoker's paradox in COVID-19 by a greater cross immunity due to a larger number, or more recent infections by common cold coronaviruses than the non-smoking population. This manuscript allow understand potential unrevealed mechanism for low prevalence of current smokers among SARS-CoV-2 patients.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gonzalez-Rubio</LastName><ForeName>Jesús</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9914-2505</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, Faculty of Medicine of Albacete, Neurophysiology &amp; Behavior Lab, Institute of Biomedicine (IB), University of Castilla-La Mancha, Albacete, Spain. jesus.gonzalez@uclm.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Navarro-López</LastName><ForeName>Juan D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-1877-7833</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, Faculty of Medicine of Ciudad Real, Neurophysiology &amp; Behavior Lab, Institute of Biomedicine (IB), University of Castilla-La Mancha, Ciudad Real, Spain. Juan.Navarro@uclm.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiménez-Díaz</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9121-0334</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, Faculty of Medicine of Ciudad Real, Neurophysiology &amp; Behavior Lab, Institute of Biomedicine (IB), University of Castilla-La Mancha, Ciudad Real, Spain. Lydia.Jimenez@uclm.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Najera</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9939-6003</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, Faculty of Medicine of Albacete, Neurophysiology &amp; Behavior Lab, Institute of Biomedicine (IB), University of Castilla-La Mancha, Albacete, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="Y">Smoking</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074285" MajorTopicYN="Y">Smokers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003139" MajorTopicYN="N">Common Cold</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">229E</Keyword><Keyword MajorTopicYN="N">Cross-immunity</Keyword><Keyword MajorTopicYN="N">HKU1</Keyword><Keyword MajorTopicYN="N">NL63</Keyword><Keyword MajorTopicYN="N">OC43</Keyword><Keyword MajorTopicYN="N">Smoker</Keyword><Keyword MajorTopicYN="N">Smoker’s paradox in COVID-19</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39420134</ArticleId><ArticleId IdType="pmc">PMC11487265</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75632-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75632-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tang, G., Liu, Z. &amp; Chen, D. Human coronaviruses: origin, host and receptor. J. Clin. Virol.155, 105246 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9301904</ArticleId><ArticleId IdType="pubmed">35930858</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui, J., Li, F. &amp; Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol.17, 181–192 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097006</ArticleId><ArticleId IdType="pubmed">30531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Teran-Tinedo, J. R. et al. Clinical characteristics and respiratory care in hospitalized vaccinated SARS-CoV-2 patients. eClinicalMedicine48, (2022). 10.1016/j.eclinm.2022.101444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9121909</ArticleId><ArticleId IdType="pubmed">35611064</ArticleId></ArticleIdList></Reference><Reference><Citation>Killerby, M. E. et al. Human coronavirus circulation in the United States 2014–2017. J. Clin. Virol.101, 52–56 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7106380</ArticleId><ArticleId IdType="pubmed">29427907</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh, K., Perlman, S., Monto, A. &amp; Englund, J. A. A proposal to refer to four coronaviruses of limited human virulence common cold coronaviruses. J. Infect. Dis.jiac355. 10.1093/infdis/jiac355 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494316</ArticleId><ArticleId IdType="pubmed">36052654</ArticleId></ArticleIdList></Reference><Reference><Citation>Arcavi, L. &amp; Benowitz, N. L. Cigarette smoking and infection. Arch. Intern. Med.164, 2206–2216 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15534156</ArticleId></ArticleIdList></Reference><Reference><Citation>Almirall, J., Serra-Prat, M., Bolibar, I. &amp; Balasso, V. Risk factors for community-acquired pneumonia in adults: a systematic review of Observational studies. Respiration. 94, 299–311 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28738364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence, H., Hunter, A., Murray, R., Lim, W. S. &amp; McKeever, T. Cigarette smoking and the occurrence of influenza - systematic review. J. Infect.79, 401–406 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31465780</ArticleId></ArticleIdList></Reference><Reference><Citation>Alraddadi, B. M. et al. Risk factors for primary Middle East Respiratory Syndrome Coronavirus illness in humans, Saudi Arabia, 2014. Emerg. Infect. Dis.22, 49–55 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4696714</ArticleId><ArticleId IdType="pubmed">26692185</ArticleId></ArticleIdList></Reference><Reference><Citation>Farsalinos, K. et al. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther. Adv. Chronic Dis.11, 2040622320935765 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318805</ArticleId><ArticleId IdType="pubmed">32637059</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Rubio, J. et al. A systematic review and Meta-analysis of Hospitalised current smokers and COVID-19. Int. J. Environ. Res. Public. Health. 17, 7394 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7601505</ArticleId><ArticleId IdType="pubmed">33050574</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons, D., Shahab, L., Brown, J. &amp; Perski, O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with bayesian meta-analyses (version 7). Addict. Abingdon Engl.. 10.1111/add.15276 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590402</ArticleId><ArticleId IdType="pubmed">33007104</ArticleId></ArticleIdList></Reference><Reference><Citation>Umnuaypornlert, A., Kanchanasurakit, S., Lucero-Prisno, D. E. &amp; Saokaew, S. Smoking and risk of negative outcomes among COVID-19 patients: a systematic review and meta-analysis. Tob. Induc. Dis.19, 9 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857247</ArticleId><ArticleId IdType="pubmed">33551713</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Wolff, K. C. et al. Tobacco Smoking and Risk of SARS-CoV-2 infection and disease severity among adults in an Integrated Healthcare System in California. Nicotine Tob. Res.ntac090. 10.1093/ntr/ntac090 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9825324</ArticleId><ArticleId IdType="pubmed">35368066</ArticleId></ArticleIdList></Reference><Reference><Citation>Usman, M. S. et al. Is there a smoker’s paradox in COVID-19? BMJ Evid. -Based Med.26, 279–284 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32788164</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Rubio, J. et al. Response to the comment on a systematic review and Meta-analysis of Hospitalised current smokers and COVID-19. Int. J. Environ. Res. Public. Health. 17, 9574 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767365</ArticleId><ArticleId IdType="pubmed">33371358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Rubio, J. et al. Cytokine release syndrome (CRS) and nicotine in COVID-19 patients: trying to calm the storm. Front. Immunol.11, 1359 (2020). 10.3389/fimmu.2020.01359 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300218</ArticleId><ArticleId IdType="pubmed">32595653</ArticleId></ArticleIdList></Reference><Reference><Citation>Labro, G. et al. Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. Intensive Care Med.48, 876–887 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9177407</ArticleId><ArticleId IdType="pubmed">35676335</ArticleId></ArticleIdList></Reference><Reference><Citation>Akerström, S. et al. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J. Virol.79, 1966–1969 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544093</ArticleId><ArticleId IdType="pubmed">15650225</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell181, 1489 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol.20, 615–632 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472682</ArticleId><ArticleId IdType="pubmed">32887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Poland, G. A., Ovsyannikova, I. G. &amp; Kennedy, R. B. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 396, 1595–1606 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7553736</ArticleId><ArticleId IdType="pubmed">33065034</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam, M. A. et al. Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents. Sci. Rep.13, 18644 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10616235</ArticleId><ArticleId IdType="pubmed">37903828</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell, A. C. et al. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nat. Immunol.23, 40–49 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8709786</ArticleId><ArticleId IdType="pubmed">34937928</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher, D. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev.4, 1 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320440</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational studies in Epidemiology (MOOSE) group. JAMA. 283, 2008–2012 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>HIGGINS, J. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration. Httpwwwcochrane-Handbookorg (2008).</Citation></Reference><Reference><Citation>L’Abbé, K. A., Detsky, A. S. &amp; O’Rourke, K. Meta-analysis in clinical research. Ann. Intern. Med.107, 224–233 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3300460</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouvier, M. et al. Species-specific clinical characteristics of human coronavirus infection among otherwise healthy adolescents and adults. Influenza Other Respir Viruses. 12, 299–303 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5820427</ArticleId><ArticleId IdType="pubmed">29350887</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeça, T. K., Carraro, E., Watanabe, A., Granato, C. &amp; Bellei, N. Infections with human coronaviruses NL63 and OC43 among hospitalised and outpatient individuals in São Paulo, Brazil. Mem. Inst. Oswaldo Cruz. 107, 693–694 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22850964</ArticleId></ArticleIdList></Reference><Reference><Citation>Dove, M. S., Leistikow, B. N., Khan, N. &amp; Tong, E. K. Current smoking and risk of coronavirus infection and illness in a highly controlled challenge study: a re-analysis of the British Cold Study. Nicotine Tob. Res.ntac148. 10.1093/ntr/ntac148 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9619420</ArticleId><ArticleId IdType="pubmed">36194540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorse, G. J., Donovan, M. M., Patel, G. B., Balasubramanian, S. &amp; Lusk, R. H. Coronavirus and other respiratory illnesses comparing older with young adults. Am. J. Med.128, 1251e11–1251e20 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7093847</ArticleId><ArticleId IdType="pubmed">26087047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwar, A., Selvaraju, S. &amp; Esper, F. Human Coronavirus-HKU1 infection among adults in Cleveland, Ohio. Open. Forum Infect. Dis.4, ofx052 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466428</ArticleId><ArticleId IdType="pubmed">28616442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozak, R. et al. Severity of coronavirus respiratory tract infections in adults admitted to acute care in Toronto, Ontario. J. Clin. Virol.126, 104338 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142695</ArticleId><ArticleId IdType="pubmed">32278299</ArticleId></ArticleIdList></Reference><Reference><Citation>Reina, J., López-Causapé, C., Rojo-Molinero, E. &amp; Rubio, R. Clinico-epidemiological characteristics of acute respiratory infections caused by coronavirus OC43, NL63 and 229E. Rev. Clin. Esp.214, 499–504 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094643</ArticleId><ArticleId IdType="pubmed">34170982</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo, P. C. Y. et al. Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J. Infect. Dis.192, 1898–1907 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110183</ArticleId><ArticleId IdType="pubmed">16267760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan, Y. et al. Respiratory virus is a real pathogen in immunocompetent community-acquired pneumonia: comparing to influenza like illness and volunteer controls. BMC Pulm Med.14, 144 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236731</ArticleId><ArticleId IdType="pubmed">25178477</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoult, D., Zumla, A., Locatelli, F., Ippolito, G. &amp; Kroemer, G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell. Stress. 4, 66–75 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7064018</ArticleId><ArticleId IdType="pubmed">32292881</ArticleId></ArticleIdList></Reference><Reference><Citation>Severance, E. G. et al. Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. Clin. Vaccine Immunol. CVI. 15, 1805–1810 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593164</ArticleId><ArticleId IdType="pubmed">18945884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrusková, J., Heinz, F., Svandová, E. &amp; Pennigerová, S. Antibodies to human coronaviruses 229E and OC43 in the population of C.R. Acta Virol.34, 346–352 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">1981445</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourez, T. et al. Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43. J. Virol. Methods. 139, 175–180 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112889</ArticleId><ArticleId IdType="pubmed">17079026</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt, O. W., Allan, I. D., Cooney, M. K., Foy, H. M. &amp; Fox, J. P. Rises in titers of antibody to human coronaviruses OC43 and 229E in Seattle families during 1975–1979. Am. J. Epidemiol.123, 862–868 (1986).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110132</ArticleId><ArticleId IdType="pubmed">3008551</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan, D. H., Kwong, A. J., Hansbro, P. M. &amp; Britton, W. J. No smoke without fire: the impact of cigarette smoking on the immune control of tuberculosis. Eur. Respir Rev.31, 210252 (2022). 10.1183/16000617.0252-2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9488690</ArticleId><ArticleId IdType="pubmed">35675921</ArticleId></ArticleIdList></Reference><Reference><Citation>Severance, E. G. et al. Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr Bull.37, 101–107 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3004184</ArticleId><ArticleId IdType="pubmed">19491313</ArticleId></ArticleIdList></Reference><Reference><Citation>Filik, R. et al. The cardiovascular and respiratory health of people with schizophrenia. Acta Psychiatr Scand.113, 298–305 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16638074</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet, M., Luciano, S., Geddes, J. R. &amp; Harrison, P. J. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 8, 130–140 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. W. et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 7, 1025–1031 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498216</ArticleId><ArticleId IdType="pubmed">32950066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavinder, J. J. &amp; Ippolito, G. C. Boosted immunity to the common cold might protect children from COVID-19. Nat. Immunol.23, 8–10 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34937927</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam, M. A. A review of SARS-CoV-2 variants and vaccines: viral properties, mutations, vaccine efficacy, and safety. Infect. Med.2, 247–261 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10774670</ArticleId><ArticleId IdType="pubmed">38205179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>